Pilot Study of Anxiety, Depression, and Quality of Life in Patients with the Diagnosis of Metastatic Uveal Melanoma

Date 22 October 2018
Event ESMO 2018 Congress
Session Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Topics Melanoma
Psychosocial Aspects of Cancer
Presenter Regine Nshimiyimana
Citation Annals of Oncology (2018) 29 (suppl_8): viii557-viii561. 10.1093/annonc/mdy296
Authors R. Nshimiyimana1, C.E. Guzzetta2, M. Brown3, Q. Zhou4, J.M. Johnson1, T. Sato5, S. Keith6
  • 1Medical Oncology, Kimmel Cancer Center-Thomas Jefferson University, 19107 - Philadelphia/US
  • 2School Of Nursing, The George Washington University, 20006 - Washington DC/US
  • 3Nursing, MedStar Health, 21044 - Columbia/US
  • 4School Of Nursing, Virginia Science And Technology Campus, The George Washington University, 20147 - Ashburn/US
  • 5Medical Oncology, Kimmel Cancer Center-Thomas Jefferson University, 19101 - Philadelphia/US
  • 6Biostatistics, Thomas Jefferson University & Jefferson Health, 19101 - Philadelphia/US



Awareness of a patient’s anxiety, depression, and quality of life (QOL) in those with metastatic uveal melanoma (MUM) can influence care that meets patients’ bio-psycho-social-spiritual needs. Objectives: To measure the level of anxiety, depression, and QOL in MUM patients and explore differences by gender, age range, time to metastatic disease, and duration of illness since metastasis.


We used a descriptive-comparative design. From 9/1/2017 - 12/1/ 2017, a convenience sample of 70 MUM patients aged ≥ 18 years, treated at a Mid-Atlantic hospital were invited to complete a combined survey of the Hospital Anxiety and Depression Scale and the World Health Organization Quality of Life-BREF.


There were 65 respondents (93% response rate). 30.8% (n = 20) had at least borderline anxiety, 13.8% (n = 9) had at least borderline depression, and 32.3% (n = 21) had a decrease in global QOL. Patients aged 18 to ≤ 60 years had a significantly higher anxiety score (7.52 ± 3.65; p = 0.003) and lower QOL in environmental health (32.48 ± 5.23; p = 0.006). There was a significant difference in anxiety scores by the duration of illness since metastasis (< 1 year [7.79 ± 3.72], >1 year to < 5 years [5.75 ± 3.45], > 5 years [3.70 ± 2.79]; p = 0.01). No differences were found by gender or time to metastatic disease.


Up to 30% of participants had at least borderline anxiety and a decreased global QOL while up to 10% had at least borderline depression. These findings support the integration of bio-psycho-social-spiritual practices in the care of MUM patients.

Clinical trial identification

Legal entity responsible for the study

Regine Nshimiyimana.


Has not received any funding.

Editorial Acknowledgement

Cathie E Guzzetta, PhD, RN, FAAN Mary-Michael Brown, DNP, RN Qiuping Zhou, PhD, RN Jennifer M. Johnson, MD, PhD, FACP Takami Sato, MD, PhD Scott W. Keith, PhD.


All authors have declared no conflicts of interest.